

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

1 May 2013

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

Dear Madam

PRESENTATION AT EUROPEAN LIVER CONFERENCE

Biotron Limited (ASX:BIT) has presented data from its BIT225 Hepatitis C virus (HCV) program at the International Liver Congress 2013 held recently in Amsterdam, the Netherlands.

The data presented by Biotron at the congress, which is available on the Company's website, includes further results from the 28-day dosing HCV trial (BIT225-005) of BIT225 in combination with the approved standard treatment of interferon and ribavirin (IFN/RBV).

As previously advised, 100% of HCV-infected trial participants who received 400mg BIT225 plus IFN/RBV had undetectable levels of virus at the 48 week time point compared to 75% of those who received placebo plus IFN/RBV.

The latest data provides further information from this important study. During the trial, participants were dosed twice daily with BIT225. Analysis of the pharmacokinetic data, which measures the drug levels in the blood after dosing, indicates that there is the potential for less frequent dosing with BIT225.

In addition, virus samples isolated from the blood of trial participants were analysed to see if any resistance to BIT225 was generated after 28 days of exposure to the drug. Drug resistance can be an issue with antiviral drugs, limiting their effectiveness in the longer term. The data presented at the congress indicate that no resistance to BIT225 was generated during the trial.


The congress annually attracts in excess of 9,000 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.

Biotron recently announced positive headline data from its Phase 1b/2a trial of BIT225 in HIV-infected subjects. BIT225 targets HIV in long-lived virus reservoir cells, and may be useful in future elimination strategies.

A Phase 2 trial of BIT225 in HIV/HCV co-infected patients is currently in progress.

For further information, contact Dr Michelle Miller, Managing Director, on 61 (0)412 313 329.

Yours sincerely

A handwritten signature in black ink, appearing to read 'PJN', with a stylized flourish at the end.

Peter J. Nightingale
Company Secretary

pjn7207

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.